Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

Nagase Viita to Launch Injectable-grade Pharmaceutical Excipient "SUCROSE SG" in…

Sucrose is widely used as a stabilizer in biopharmaceuticals, a rapidly growing market. It helps maintain the quality of antibody drugs and lipid nanoparticles (LNPs) formulated with nucleic acid, such as COVID-19 vaccines. Sucrose is widely used as a stabilizer in biopharmaceuticals, a rapidly growing market. It helps maintain the quality of antibody drugs and lipid nanoparticles (LNPs) formulated with nucleic acid, such as COVID-19 vaccines. Since its founding, sustainability and...

Invitation to attend the special shareholders' meeting of the Company to be held…

REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the special shareholders' meeting of the Companyto be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p...

BIOVAXYS ANNOUNCES PRIVATE PLACEMENT OFFERING

Each Unit consists of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant shall be convertible into an additional Share at an exercise price of $0.15 for a period of 24 months from the date of issuance. Each Unit consists of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a " Warrant ")…

Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by…

Key Takeaways from the Peripheral Nerve Injuries Market Report Key Takeaways from the Peripheral Nerve Injuries Market Report Discover which therapies are expected to grab the major peripheral nerve injuries market share @ Peripheral Nerve Injuries Market Report Peripheral Nerve Injuries Overview Peripheral nerve injuries involve damage to the nerves outside the brain and spinal cord, which can disrupt motor function, sensory perception, and autonomic processes in the affected areas...

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility…

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m...

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

The investment will enable ATB to expand and enhance the ATBioFarm platform, as well as to accelerate development of its unique weaponized antibodies for oncology and immunology applications. ATB's research and development operations will be extended to Ghent and will continue in Marche-en-Famenne, where the Company is setting up a cutting-edge pilot manufacturing facility. The investment will enable ATB to expand and enhance the ATBioFarm platform, as well as to accelerate development of its...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 18 November 2024– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential…

Since its inception in 2021, VelaVigo has built an extensive pipeline of over ten FIC/BIC multi-specific antibodies and ADC molecules for oncology and autoimmune diseases. It has also set up VelaVigo Bio, Inc. in the US to drive clinical development and partnership globally. Since its inception in 2021, VelaVigo has built an extensive pipeline of over ten FIC/BIC multi-specific antibodies and ADC molecules for oncology and autoimmune diseases. It has also set up VelaVigo Bio, Inc. in the US…

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of…

Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School (USA) commented, "The FDA's decision to designate VAD044 as a Fast Track product for the treatment of HHT underscores its potential to be the first ever approved treatment for this debilitating genetic disease." Dr.Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General…

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of…

Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School (USA) commented, "The FDA's decision to designate VAD044 as a Fast Track product for the treatment of HHT underscores its potential to be the first ever approved treatment for this debilitating genetic disease." Dr.Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General…

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Eli Ben-HarooshAsher Holzer Orit Berger Christina Cameron Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company: Eli Ben-Haroosh, Chief Executive OfficerSophya...

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Eli Ben-HarooshAsher Holzer Orit Berger Christina Cameron Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company: Eli Ben-Haroosh, Chief Executive OfficerSophya...

Novonesis will host an educational conference call on Energy on December 18

Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will share insights about the industry, its development, and Novonesis' integral part of the industry's value chain. The session will be hosted as a conference call on December 18 at 15:00 CET.To join the live webcast, please clickhere.To register and receive access details for the conference call, please clickhere. Attachment 2024_Spotlight_Energy ...

Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System

The Persona Revision Knee offers a personalized fit and optimized function for patients undergoing revision knee surgery. The modular system allows for intraoperative flexibility, so surgeons can address a wide range of complex cases with precision and ease. The system features Zimmer Biomet's proprietary Trabecular Metal™ Technology, which promotes long-term bone in-growth and improves implant fixation.1 2 3 The Persona Revision Knee offers a personalized fit and optimized function for...

Immatics Announces Third Quarter 2024 Financial Results, Business Update and…

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation trial, demonstrating a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melanoma patients; early...

MolecuLight® Applauds New CMS Local Coverage Determination (LCD) Changes for…

Key benefits of using MolecuLight® in conjunction with graft/skin substitute therapy: Key benefits of using MolecuLight® in conjunction with graft/skin substitute therapy: "We are committed to supporting healthcare providers in delivering optimal wound care," said Anil Amlani, CEO at MolecuLight. "Our technology empowers clinicians to make evidence-based decisions and improve patient outcomes. We are confident that MolecuLight will play a crucial role in meeting the new LCD…

Abbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland

Speaking at the event, An Taoiseach, Simon Harris, TD, said, "Abbott, which has been in Ireland since 1946, is one of the longest-established global companies and largest employers in our country. This latest investment is a further vote of confidence in Ireland as a location for world-class advanced manufacturing and healthcare businesses. With the opening of this new site, Ireland is now at the global centre of diabetes care." Speaking at the event, An Taoiseach,Simon Harris, TD…

Ulike brings unmissable Black Friday deals to UK beauty lovers, featuring the…

With Ulike's patented Sapphire Ice Cooling technology, the Air 3 and Air 3 Deluxe keep the skin cool throughout treatment, making hair removal nearly painless, even on sensitive areas. The advanced IPL technology visibly reduces hair in as little as three weeks, achieving up to 93% reduction after four weeks by targeting hair at the root. The device also includes AutoGlide mode, enabling seamless, full-body treatments in just 13 minutes, along with three adjustable power modes to personalise the…

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Eli Ben-HarooshAsher Holzer Orit Berger Christina Cameron Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company: Eli Ben-Haroosh, Chief Executive OfficerSophya...

EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable…

EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix's Phase 2 TrIuMPH trial assessing EBX-102-02EnteroBiotix completed enrolment ahead of its planned schedule, dosing 62 participants with constipation predominant IBS (IBS-C) and 60 participants with diarrhoea predominant IBS (IBS-D)Topline data expected to readout in Q1 2025Glasgow, Scotland –...

Nagase Viita to Launch Injectable-grade Pharmaceutical Excipient "SUCROSE SG" in…

ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore…

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont…

Dapirolizumab Pegol Phase 3 Data Presented at the American College of…

Invitation to attend the special shareholders' meeting of the Company to be held…

BIOVAXYS ANNOUNCES PRIVATE PLACEMENT OFFERING

Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by…

Publication relating to transparency notifications

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility…

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

Novo Nordisk A/S - share repurchase programme

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential…

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of…

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of…

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Novonesis will host an educational conference call on Energy on December 18

Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System

Immatics Announces Third Quarter 2024 Financial Results, Business Update and…

MolecuLight® Applauds New CMS Local Coverage Determination (LCD) Changes for…

Abbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland

Ulike brings unmissable Black Friday deals to UK beauty lovers, featuring the…

Zero Candida Applies to List its Shares on the TSX Venture Exchange

EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable…